Skip to main content

LENZ Therapeutics, Inc.

corporate_fare Company Profile

LENZ Therapeutics, Inc.

LENZ·NASDAQ·Life Sciences·CIK 0001815776

LENZ Therapeutics, Inc. is a commercial pharmaceutical company that develops and sells innovative therapies to improve vision. On July 31, 2025, the U.S. Food and Drug Administration (FDA) approved VIZZ (aceclidine ophthalmic solution) 1.44%, previously known as LNZ100. VIZZ is the first and only FDA-approved aceclidine-based eye drop for treating presbyopia, a condition affecting an estimated 1.8 billion people globally and 128 million people in the U.S. The company is selling VIZZ in the U.S. and is forming international licensing and distribution partnerships to make VIZZ available worldwide. LENZ commercially launched VIZZ in the U.S. in August 2025, with sales and marketing activities targeting eye care professionals starting immediately after approval. Professional product samples were distributed by the sales force to optometrists and ophthalmologists, and commercial product shipments to customers through their e-pharmacy partner began in October 2025. VIZZ became widely available in retail pharmacies starting in November 2025. VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop designed to restore clear near vision for up to 10 hours. Its active ingredient, aceclidine, is a new chemical entity (NCE) in the U.S. and is a predominantly pupil-selective miotic that interacts with the iris with minimal ciliary muscle stimulation. VIZZ contracts the iris sphincter muscle, creating a pinhole effect and achieving a sub-2mm pupil, which extends depth of focus to significantly improve near vision without causing a myopic shift. The FDA approval of aceclidine marks a global first for the treatment of presbyopia.

LENZ Therapeutics, Inc. (NASDAQ:LENZ) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 14 items for LENZ at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-02, rated 8/10. Across its 14 most recent items scored 7 or higher, the top rating is 8/10, with 9 rated 8 or above. Recent SEC coverage for LENZ spans SCHEDULE 13D/A, 8-K, 10-Q, 10-K.

Recent high-impact activity:

  • RA Capital Exits 5% Stake, Dumping 4.18M LENZ Shares in Three Days
  • LENZ Misses Q3 Estimates as Revenue Falls 72.9%
  • LENZ Cuts 75% of Staff, CEO Out Dec. 1 as 2027 Opex Target Falls to $70-75M
  • LENZ Q3 Sales Up 50% but CEO Exits as Reorg Targets 50% Cost Cut
  • LENZ Q2 Revenue Hits $5.5M on VIZZ Growth, Loss Widens to $31.9M

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$19.09M
Net Income
-$82.13M
Diluted EPS
-$2.85
Op. Cash Flow
-$69.17M
Free Cash Flow
-$70M
Gross Profit
$18.67M
Operating Income
-$91.14M
Cash & Equivalents
$25.18M
Debt / Equity
0.00×
Net Margin
-430.3%
Shares Outstanding
31.34M sh
Source: 10-K · filed 2026-03-24 · accession 0001815776-26-000011

Short Interest & Short Volume

5.60 days to cover

FINRA reported short interest of 7,069,790 shares in LENZ as of the October 30, 2026 settlement, a 22.3% decrease from the prior period — about 5.6 days to cover at its recent average daily volume. On November 20, 2026, 62.8% of LENZ volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)7,069,790 shares as of October 30, 2026
Change vs prior period▼ 22.3%
Days to cover5.60 at avg daily volume of 1,262,730
Daily short volume (FINRA facilities)62.8% of 312,195 shares on November 20, 2026
5-day average short volume58.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with L →
$3 +1.18% today
52-week range · as of 2026-11-02 $2.8 – $32.13
Market cap
$93.16M
Volume
951.8K (0.9× avg)
3-mo avg 1.1M
Live data · 2026-11-21 23:43 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed LENZ - Latest Insights

LENZ
Nov 02, 2026, 5:45 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $3.12
Real-time Price: $3.00 info
Change: -$0.120 (-4%) info
Market Cap: $93.162M info
LENZ
Oct 29, 2026, 8:01 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $3.00
Real-time Price: $3.00 info
Change: $0 (0%) info
Market Cap: $93.162M info
LENZ
Oct 28, 2026, 4:34 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.06
Real-time Price: $3.00 info
Change: -$0.060 (-2%) info
Market Cap: $93.162M info
LENZ
Oct 28, 2026, 4:30 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.06
Real-time Price: $3.00 info
Change: -$0.060 (-2%) info
Market Cap: $93.162M info
LENZ
Aug 11, 2026, 4:21 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $5.47
Real-time Price: $3.00 info
Change: -$2.47 (-45%) info
Market Cap: $93.162M info
LENZ
Aug 11, 2026, 4:13 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $5.47
Real-time Price: $3.00 info
Change: -$2.47 (-45%) info
Market Cap: $93.162M info
LENZ
Jul 06, 2026, 8:15 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $5.85
Real-time Price: $3.00 info
Change: -$2.85 (-49%) info
Market Cap: $93.162M info
LENZ
Jun 24, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $5.91
Real-time Price: $3.00 info
Change: -$2.91 (-49%) info
Market Cap: $93.162M info
LENZ
Jun 07, 2026, 7:30 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $6.90
Real-time Price: $3.00 info
Change: -$3.90 (-57%) info
Market Cap: $93.162M info
LENZ
May 11, 2026, 4:10 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $9.29
Real-time Price: $3.00 info
Change: -$6.29 (-68%) info
Market Cap: $93.162M info
LENZ
Mar 24, 2026, 4:10 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $8.86
Real-time Price: $3.00 info
Change: -$5.86 (-66%) info
Market Cap: $93.162M info
LENZ
Mar 24, 2026, 8:10 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $10.55
Real-time Price: $3.00 info
Change: -$7.55 (-72%) info
Market Cap: $93.162M info
LENZ
Mar 24, 2026, 8:01 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $10.79
Real-time Price: $3.00 info
Change: -$7.79 (-72%) info
Market Cap: $93.162M info
LENZ
Jan 07, 2026, 5:10 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $16.91
Real-time Price: $3.00 info
Change: -$13.91 (-82%) info
Market Cap: $93.162M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets